Beyond Algorithms: How AI and Human Expertise Transform Clinical Trials in R&D

Deloitte’s Life Sciences and Healthcare Predictions 2030 explores how the world could look in 2030, what it might feel like for different stakeholders in the health ecosystem, the evidence today that informs the views of tomorrow and how AI technologies, specifically GenAI, might help bring the future closer. Specifically, Karen Taylor’s talk will focus on how the R&D function of the pharmaceutical industry is transforming, driven by the convergence of AI and human expertise. By harnessing the power of AI, researchers can identify potential drug candidates, improve recruitment and retention of trial participants, predict treatment outcomes, and tailor therapies to individual patients. However, the potential of AI will only be realised when humans are kept in-the-loop. Clinicians and scientists play a crucial role in validating AI-driven insights, ensuring ethical considerations are met, and translating research findings into real-world clinical practice. Join Karen Taylor to learn how this synergy between AI and human expertise is not just accelerating the pace of innovation but also improving the quality, safety, and efficacy of new therapies, ultimately leading to better patient outcomes.